Pharmaceutical Technology

NOVEMBER 4, 2022

As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. The expertise in procurement for new projects is a definite advantage with choosing a CMO like Baxter BioPharma Solutions.

Biopharma 52

Biopharma Manufacturing Media Pharmaceutical 52

Clarivate

MARCH 14, 2024

Research is raising concerns about PFAS use Similarly, PFAS (per- and polyfluoroalkyl substances) in pharmaceutical packaging have recently come under scrutiny, leading to significant regulatory changes. With Europe taking the lead in introducing draft regulations on PFAS, will other countries and regions implement their own regulations?

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52

Clarivate

NOVEMBER 13, 2023

The purpose of clinical trials is to understand the efficacy and safety of treatments for the patients who need them. Last year alone the Clarivate COA team conducted over 300 interviews with patients, caregivers or healthcare professionals. The PFDD series will eventually take the place of the PRO Guidance for Industry.

Patients 52

Patients Food and Drug Administration FDA Safety 52

PM360

SEPTEMBER 15, 2022

But battling information asymmetry is one of the best ways to address the ongoing inequities in our healthcare system. But to shift the industry’s approach to healthcare, all stakeholders must move the efforts, attention, and education necessary to find a common ground and ensure that the patients’ interests are always driving development.

Patients 98

Patients Healthcare Healthcare Marketing 98

European Pharmaceutical Review

FEBRUARY 21, 2023

Crucially, January 2023 marked a key moment: the Medicines and Healthcare products Regulatory Agency (MHRA) granted Celadon Pharmaceuticals the first good manufacturing practice (GMP) registration since legalisation in 2018 for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API). He founded Celadon in 2018.

Medicine 128

Medicine Manufacturing Specialization Pharmaceutical 128

Clarivate

OCTOBER 19, 2023

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).

Networking 59

Networking Consulting Safety Side effects 59

pharmaphorum

AUGUST 4, 2022

This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches. Raising the profile.

Recruitment 94

Recruitment Pharma Training Pharmaceutical manufacturing 94

Clarivate

NOVEMBER 10, 2022

The purpose of clinical trials is to understand the efficacy and safety of treatments for the patients who need them. The work, said lead investigator Brett King, Associate Professor at Yale Dermatology, “helped change the landscape of alopecia areata forever.”. The regulatory landscape around COAs is fast evolving.

Patients 52

Patients Food and Drug Administration FDA Safety 52

Clarivate

OCTOBER 10, 2022

Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

pharmaphorum

JANUARY 6, 2023

Veeva’s industry experts share their predictions about how breaking down silos across clinical, regulatory, safety, and quality teams will benefit patients. Emerging and mid-sized companies launching products in Europe are also navigating a healthcare ecosystem that is complex and fragile due to regulatory and cost pressures.

Safety 107

Safety Management Patients Biopharma 107

PM360

SEPTEMBER 28, 2022

At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Now, as the President of Accord BioPharma , the U.S.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

MAY 13, 2024

Key takeaways Although growth in commercial and exchange enrollment will blunt some impacts, an increased uninsured rate will lead to increased uncompensated care, adding to cost pressures for health systems, especially safety-net hospitals that will see the highest volume of people cut from Medicaid. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Rishi Kadiwar.

Patients 59

Patients Pharma Education Media 59

pharmaphorum

SEPTEMBER 28, 2022

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset. In recent years, the biopharma market has become progressively complex.

Biopharma 52

Biopharma Side effects Consulting Pharmaceutical products 52

pharmaphorum

SEPTEMBER 12, 2022

Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. Knowledge can change the course of healthcare for all and alter the course of care for individuals in need. Tailored oncology.

Patients 102

Patients Medicine FDA Healthcare 102

PM360

JULY 13, 2023

However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. What Other Developments Within Oncology Excite You? What Is Your Company Currently Working On?

Patients 98

Patients Engineering Side effects Leads 98

European Pharmaceutical Review

DECEMBER 26, 2023

The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population. million for Hemgenix [AAV5-hFIX-Padua]). million for Hemgenix [AAV5-hFIX-Padua]). This enhances the commercial viability of USP.

Manufacturing 83

Manufacturing Safety Patients Competition 83

Clarivate

JULY 6, 2023

Precision medicine The biopharma industry is increasingly moving towards a precision medicine approach that enables patients to be treated at an earlier stage of disease for better outcomes. This process provides crucial spatial context to molecular data, enhancing our understanding of diseases and informing clinical decision-making.

Consulting 52

Consulting Medicine Biopharma Patients 52

Medgadget

MARCH 2, 2023

This leads to substantial damage to healthy tissues and too often results in poor outcomes. This will hopefully lead to an FDA approval for its first indication, after which Alpha TAU plans on expanding to other types of cancer and geographic regions such as Europe and Japan. which are currently recruiting patients.

Manufacturing 83

Manufacturing Leads Patients Medicine 83

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Healthcare 52

Healthcare Healthcare Medicine Biopharma 52